Faith and meaning: a new support approach for muslim cancer patients
NCT ID NCT04435444
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests a support program designed to help Muslim patients with stage III or IV cancer find meaning and cope with their illness. Participants attend up to three counseling sessions that blend spiritual and psychological support. The goal is to see if this faith-based approach improves well-being and quality of life compared to standard patient education materials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Masterful supportive care (faith-based counseling sessions)
- What this could lead to
- If effective, this program could offer a culturally tailored way to help Muslim patients with advanced cancer find meaning and cope better.
- What could go wrong
- This is a very small pilot study with only 19 participants, so results may not apply broadly. The intervention may not provide more benefit than standard support materials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
19 people
The number who actually took part.
- Started
-
Jun 2020
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥ 18 years of age * identify, either as self-report or on the MSKCC EMR, as Muslim * are in treatment including surveillance, for a confirmed diagnosis of stage III or IV cancer (solid or liquid) as per clinician or pathology report * have an estimated life expectancy of at least 6 months, as determined by their primary oncologist * are cognitively intact (oncologist's clinical impression or judgement of study staff) * able to speak and read English or Arabic (self-reported preference or on the MSKCC EMR system). * To assess English proficiency, participants will be asked two questions: (1) the Census limited English proficient item "How well do you speak English?" with response options "Not at all, Not well, Well, or Very well" and (2) "What is your preferred language for healthcare?" * Participants who are eligible for the study and are fluent in English will be identified by the response "Very well" to the 1st question and a response indicating English as the preferred language for healthcare. Exclusion Criteria: * Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation * patients diagnosed with primary brain tumors as per clinician report, as they may have difficulty completing the intervention and answering the questionnaires * undergoing hematopoietic stem cell transplantation (HSCT) as per clinican report or the EMR * currently in psychotherapeutic treatment. Symptoms of anxiety and depression are common among patients with stage III or IV cancer. Antidepressants, anxiolytics, and other psychotropic medications do not diminish the effects of psychotherapy; thus we will not exclude patients who are being treated with these medications, as long as they are not in psychotherapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking symptoms improve care for children with advanced cancer?
- Can a new pill boost Immunotherapy's power against advanced tumors?
- Can a DNA vaccine train the immune system to hunt down HER3-Positive cancers?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can an AI chatbot lift the spirits of advanced cancer patients?
- Can a psychedelic ease the existential weight of advanced cancer?